<DOC>
	<DOCNO>NCT03067155</DOCNO>
	<brief_summary>Viral infection remain important cause morbidity mortality allogeneic stem cell transplantation ( SCT ) , especially myelo-ablative condition donor antigen-mismatched haplo-identical.. In described set patient 's immune system destroy necessary highly immuno- myelo-ablative conditioning memory infection delete . Therefore , high risk several viral infection infectious organisms.Both primary viral infection reactivations occur , patient become refractory antiviral treatment , case adequate antiviral treatment unavailable toxic . In study , investigator target CMV , refractory CMV infection disease accompany extremely high mortality rate therefore development new treatment approach require . Despite available antiviral drug , considerable number patient face insufficient control CMV reactivation SCT . Because reconstitution CMV-specific T cell confer protection development CMV disease SCT , attempt make restore antiviral immunity direct infusion CMV-specific T cell . Most clinical cellular immunotherapy protocol CMV treatment use CMV-specific cytotoxic CD8+ T-cell line generate repetitive vitro stimulation CMV antigens success . Despite proven efficacy , use cellular therapy clinic limit , approach time labor consume require specialize facility allow handle therapeutic cell accord good manufacturing practice . In addition , sustain response see adoptive transfer involve cytotoxic CD8+ T cell . This phenomenon support fact recall responses latent infection depend presence CD4+ T cell help cytotoxic CD8+ T cell . An alternative approach transfer T-cell immunity isolation Ag-specific T cell ex vivo blood CMV seropositive donor , base interferon γ ( IFN-γ ) secretion T cell vitro stimulation viral Ag , result combination CD4+ T helper cytotoxic CD8+ CMV specific T cell . Using strategy , short-term ex vivo protocol develop isolation pp65 ( CMV immunodominant protein ) -specific T cell . Since , several center use protocol clinic , infuse low number pp65-specific T cell , able restore protective T-cell immunity CMV post SCT setting patient refractory CMV disease viremia . For protocol investigator set validated method CMV-specific T-cell generation Ghent University Hospital investigator make available Belgian transplant center .</brief_summary>
	<brief_title>CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation .</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Patients : 1 . All underlying disease form indication allogeneic stem cell transplantation 2 . Underwent allogeneic stem cell transplantation donor fulfills follow criterion : CMVseropositive time transplant Age 1870 year 3 ) Having CMV reactivation primary infection disease follow characteristic : CMV PCR least twice positive AND CMV infection relapse 3 successful treatment episodes gancyclovir OR Refractory treatment available antiviral drug define follow : Persistent positive CMV PCR &gt; detection limit 14 day initiation antiviral treatment OR increase CMV viral load 7 day initiation antiviral treatment 4 ) Informed consent give Donor : 1 . Is identical donor previous stem cell transplant 2 . The donor prescreened presence sufficient number CMVspecific T cell : IFNgamma produce T cell upon CMVpp65 stimulation least twice background level ( unstimulated cell ) At least 10 event IFNgamma positive T cell measure IFNgamma produce T cell upon CMVpp65 stimulation equal high 0,1 % viable CD4+ CD8+ cell population If donor show sufficient number circulate CMVspecific cell , accord test describe 2 3 ) Only donor show sufficient number circulate CMVspecific cell , accord test describe 2 : Donor positive IgG serology CMV , IgM negative positive Donor sign informed consent donation donor lymphocyte cell Donor find fit donation medical doctor accord selection criterion conform KB annex II ( C2009/18414 ) Donor negative infectious disease marker include HCV , HBV HIVNAT testing : HBs antigen , HBc/HBs antibody , Syphilis ( TPHA equivalent ) , HVC HIV antibody . Additional testing perform negative relevant : malaria , west nile virus , trypanosomiasis , HTLV conform KB annex II ( C2009/18414 ) HCG negative within 7 day apheresis Patients : 1 . HIV , HCV , HBV positive ( HbSAg positivity vaccination allow ) 2 . Life expectancy severely limited disease malignancy viral infection 3 . Administration cytotoxic agent ( ) cytoreduction within three week prior initiation treatment expect within 8 week administration treatment 4 . Terminal organ failure except renal failure ( dialysis acceptable ) 5 . Uncontrolled infection one treat 6 . Karnofsky performance score &lt; 60 % 7 . Patient fertile man woman unwilling use contraceptive technique 12 month follow treatment 8 . Patient female pregnant breastfeed 9 . Patient active aGVHD grade 3 10 . Patient severe chronic GVHD 11 . Patient corticosteroid &gt; 0.5mg/kg . Patient still therapeutic dos immunosuppressive therapy , taper low possible dose , part standard care case CMV reactivation . 12 . Patient receive ATG &lt; 1 month prior infusion Campath &lt; 1 year prior infusion 13 . Any condition fulfil inclusion criterion Donor : 1 . Any condition fulfil inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>allogeneic stem cell transplantation</keyword>
	<keyword>CMV reactivation</keyword>
</DOC>